STE · 10-Q · 2026Q2

STERIS plc

Filed 2026-08-07 · Healthcare · View original filing on EDGAR

Ranked Events

• Capital Return ProgramImportance 58 · Surprise 42
  STERIS repurchased 0.5 million ordinary shares for $100.0 million during the first three months of fiscal 2027 under the share-repurchase program adopted by the Board on May 5, 2026. No repurchases occurred under the…
• Segment Revenue PerformanceImportance 55 · Surprise 32
  Healthcare revenue increased 7.6% to $1,048.3 million, with service, consumable, and capital equipment revenue growth of 9.6%, 9.2%, and 1.4%, respectively. Constant-currency organic Healthcare growth was 6.4%, driven…
• Geographic Market CommentaryImportance 52 · Surprise 30
  United States revenue increased 6.3% to $1,090.6 million, reflecting growth in service, consumable, and capital equipment revenues. Ireland revenue increased 28.7% to $29.0 million, with growth across service, capital…
• Income Tax Rate ChangesImportance 52 · Surprise 56
  Income tax expense increased 34.5% to $72.5 million for the three months ended June 30, 2026, from $53.9 million. The effective income tax rate increased to 26.5% from 23.3%, a 3.2-percentage-point increase. The higher…
• Acquisition / Partnership / DivestitureImportance 50 · Surprise 58
  STERIS completed three tuck-in acquisitions during the first three months of fiscal 2027 to expand Healthcare products and services. Aggregate consideration was approximately $17.3 million, including deferred and…
• Gross Margin DriversImportance 49 · Surprise 32
  Gross profit increased 8.9% to $684.2 million for the three months ended June 30, 2026, from $628.0 million. Total gross margin expanded to 45.8% from 45.1%, while product gross margin increased to 50.0% from 47.9% and…
• Headcount / RestructuringImportance 46 · Surprise 42
  STERIS’s May 2024 restructuring plan eliminated approximately 300 positions and included a strategic shift in the European Healthcare surgical business, product rationalizations, and facility consolidations. The plan…
• Operating Cash Flow TrendsImportance 45 · Surprise 40
  Cash flow from operations declined 12.6% to $367.1 million in the first three months of fiscal 2027 from $420.0 million. Free cash flow declined 14.4% to $279.6 million from $326.5 million after $87.5 million of…
• Operating Income and MarginsImportance 45 · Surprise 40
  Income from operations increased 16.2% to $285.8 million for the first three months of fiscal 2027 from $246.0 million. The improvement was driven primarily by increased pricing, volume, and productivity, partly offset…
• Revenue Performance and MixImportance 43 · Surprise 32
  Total revenue increased 7.3% year over year to $1,492.7 million in the three months ended June 30, 2026, from $1,391.1 million. Service revenue rose 7.8% to $755.5 million, consumable revenue rose 9.0% to $474.0…
• Operating Expense TrendsImportance 42 · Surprise 14
  Total operating expenses increased 4.3% to $398.3 million in the first quarter of fiscal 2027 from $382.0 million. SG&A increased 4.5% to $369.7 million, primarily because of higher compensation and benefits and…
• Trade Policy and TariffsImportance 40 · Surprise 42
  Net tariffs contributed a favorable 20 basis points to STERIS’s consolidated gross profit percentage in the three months ended June 30, 2026. The company’s corporate operating-cost reconciliation includes refunds…
• Manufacturing Capacity ExpansionImportance 37 · Surprise 42
  On August 5, 2026, STERIS announced a targeted restructuring plan to consolidate formulated-chemistry manufacturing and distribution at a new Center of Excellence in North Carolina. The plan anticipates closing…
• Liquidity and Debt PositionImportance 31 · Surprise 6
  STERIS’s debt-to-total-capital ratio was 20.9% at June 30, 2026, down from 21.5% at June 30, 2025. Net payments under credit facilities were $37.8 million in the first three months of fiscal 2027, compared with $30.5…
• Inflation Cost PressureImportance 20 · Surprise 24
  Inflation reduced STERIS’s consolidated gross profit percentage by 60 basis points in the three months ended June 30, 2026, partially offsetting pricing, productivity, and mix benefits. Healthcare operating income was…
• Products and TechnologyImportance 6 · Surprise 6
  STERIS provides infection-prevention products and services across healthcare, medical device, and pharmaceutical markets, including consumables, sterilizers, surgical tables, automated endoscope reprocessors,…

Revenue by Product (in millions)

Revenue by Geography (in millions)